CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma
L. Su, L. Wu, R. R. Lobb, P. D. Rennert, C. Ambrose
This paper introduces a CAR-T Engager protein that prevents and reverses lymphoma relapse by maintaining CD19 antigen presence on cancer cells.
bioRxiv · May 30, 2022Cancer Biology